-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the evening of July 14, Cinda Biological released an announcement stating that it will carry out a multi-level strategic cooperation with Yasheng Pharmaceutical to jointly commercialize the third-generation BCR-ABL inhibitor HQP1351 and provide the CD20 antibody Dabohua (rituximab).
On the evening of July 14, Cinda Biological released an announcement stating that it will carry out a multi-level strategic cooperation with Yasheng Pharmaceutical to jointly commercialize the third-generation BCR-ABL inhibitor HQP1351 and provide the CD20 antibody Dabohua (rituximab).
Injection) and CD47 antibody IB188 (letaplimab) and Bcl-2 inhibitor APG-2575 for clinical development
.
In addition, in view of the growth potential of Yasheng Pharmaceutical, Cinda Bio will subscribe for new shares and warrants from Yasheng Pharmaceutical
.